First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
Fig 3
GP-specific neutralizing antibody responses (psVNA); immunogenicity analysis set.
Ad26.F = Ad26.Filo; Ad26.Z = Ad26.ZEBOV; EBOV = Zaire ebolavirus; GP = glycoprotein; IC50 = 50% inhibitory concentration; Inf U = infectious units; LLOQ = lower limit of quantification; MARV = Marburg virus; MVA = MVA-BN-Filo; psVNA = pseudovirion neutralization assay; SUDV = Sudan ebolavirus. aIncludes all Group 3 participants up to and including the Day 50 time point, after which point only Group 3 participants who did not receive a third dose of vaccine/placebo on Day 92 are included. bMVA-BN-Filo at a dose 1x108 Inf U. cAll time points include only Group 3 participants who received three doses of vaccine/placebo.